The Multiple Myeloma Research Consortium (MMRC) is the first collaborative research organization of its kind. It brings together academic and community cancer centers with industry, to advance innovative Phase 1 and Phase 2 clinical trials of today’s most promising drug candidates.
Driven to achieve results
Our metrics mandate accountability and strongly promote team science. Our goal is to advance the treatment of multiple myeloma at all costs.
How it connects
MMRC Member Institutions are supported by an advanced infrastructure. It includes a cutting-edge tissue bank and IT systems that enable rapid, seamless collaboration.
The MMRC is aggressively investigating many cutting-edge cancer treatments, including molecularly targets, immune and novel agents.
We are working on a Master Protocol approach to pivotal trial design that could dramatically accelerate the development of targeted therapies. It is designed to overcome cost, patient participation, and design barriers that inhibit many clinical trials in the MMRC. Which will ultimately—by determining the best therapeutic fit for patients — improve treatment outcomes.
Also, The MMRC drives advancement through the Biotech Investment Award program (BIA). The goal of this initiative is to drive and accelerate the development of innovative and effective treatments for myeloma. This program is designed to provide resources necessary for biotechnology and pharmaceutical companies to rapidly test therapeutics in multiple myeloma. And to foster collaboration with academic myeloma experts as needed. BIA aims to remove barriers that limit the development of novel drugs for myeloma.